BiotechTube
BlueAllele

BlueAllele

San Diego, United States· Est.
blueallele.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BlueAllele is a private, pre-clinical stage biotech focused on overcoming key limitations in gene editing through its innovative PALIDON® repair template platform. The company's technology is engineered to leverage the highly active NHEJ DNA repair pathway, potentially enabling efficient gene correction for a wide range of monogenic diseases in both dividing and non-dividing cells. Led by a team with deep experience in gene editing, intellectual property, and biotech commercialization, BlueAllele is positioning itself to address a significant unmet need in the field. The company is currently in the platform development and research phase, with no disclosed clinical pipeline.

Genetic Diseases

Technology Platform

PALIDON® platform: Advanced repair template technology designed to leverage the non-homologous end joining (NHEJ) pathway for precise gene correction in both dividing and non-dividing cells.

Opportunities

The platform targets a major technical bottleneck—inefficient repair in non-dividing cells—potentially unlocking gene therapy for a vast array of monogenic diseases affecting tissues like the CNS, heart, and muscle.
Its compatibility with existing nucleases and delivery systems could enable rapid deployment across multiple disease targets and facilitate strategic partnerships.

Risk Factors

The novel PALIDON® technology is unproven in human therapeutics, carrying high technical risk.
The company operates in an intensely competitive and capital-intensive field with complex intellectual property landscapes, facing significant challenges in securing funding and achieving scientific differentiation.

Competitive Landscape

BlueAllele competes in the crowded gene editing space against well-established public companies (e.g., CRISPR Therapeutics, Intellia, Editas) and numerous startups, all focused on improving editing precision and efficiency. Its differentiation hinges on its unique NHEJ-focused repair template approach, a niche not yet dominated by major players.

More companies in CRISPR / Gene Editing →More companies in United States →